What are Polaryx Therapeutics, Inc. 's total assets?

Polaryx Therapeutics, Inc. (PLYX) holds $3.5M in total assets.

How much cash does Polaryx Therapeutics, Inc. have?

Polaryx Therapeutics, Inc. holds $3.1M in cash and equivalents.

Can Polaryx Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 3.45 — current assets exceed current liabilities.

Where does Polaryx Therapeutics, Inc. 's balance sheet data come from?

Every line is extracted from Polaryx Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Polaryx Therapeutics, Inc. PLYX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q1 '25	Q4 '24	Q3 '24
Cash and cash equivalents	$3.08M+1,132%	$5.14M+11.3%	$250K—	$4.62M—	——
Prepaid expenses and other current assets	$395K+9,775%	——	$4K—	$380K—	——
Total current assets	$3.5M—	$5.17M+3.4%	——	$5M—	——
Deferred tax assets	——	$4.74M+15.8%	——	$4.1M—	——
Total assets	$3.5M—	$5.17M+3.4%	——	$5M—	——
Accounts payable	$850K+5,100%	$470K+553%	-$17K+83.0%	$72K—	-$100.25K—
Accrued expenses	——	$21K+2,000%	——	$1K—	——
Total current liabilities	$1.01M—	$605K+109%	——	$289K—	——
Deferred tax liabilities	——	$250K-46.5%	——	$467K—	——
Total liabilities	$1.01M—	$605K+109%	——	$289K—	——
Common stock	——	$560M0.0%	——	$560M—	——
Additional paid-in capital	$104.66M—	$104.2M+9.3%	——	$95.36M—	——
Retained earnings	-$102.18M—	-$99.64M-9.9%	——	-$90.65M—	——
Total stockholders' equity	$2.49M-41.5%	$4.57M-3.1%	$4.25M—	$4.71M+269%	——
Total liabilities and stockholders' equity	$3.5M—	$5.17M+3.4%	——	$5M—	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	——	514,300,000%+52,200,000%	——	462,100,000%+461,900,000%	——
Other current assets	$33K—	$27K—	——	——	——
Deferred Tax Assets - Tax Credit Carryforwards	——	$50K+163%	——	$19K—	——
Indefinite-Lived Research and Development Assets	——	$998K-18.0%	——	$1.22M—	——
Net Operating Loss Carryforwards	——	$18.7M+19.1%	——	$15.7M—	——
Tax Credit Carryforward Valuation Allowance	——	$6.39M+31.4%	——	$4.87M—	——
Accrued Manufacturing Costs	$21K—	$21K+2,000%	——	$1K—	——
Other Commercial Liabilities	$45K—	$23K—	——	——	——
Accrued Liabilities, Current	$45K—	$23K—	——	——	——
Compensation and benefits	$21K—	$21K+2,000%	——	$1K—	——
Accrued expenses and other liabilities	$21K—	$21K-75.9%	——	$87K—	——
Common Stock Par Value Per Share	——	$0.000.0%	——	$0.00—	——
Common Stock Shares Issued	——	$47.34M+15.0%	——	$41.15M—	——
Convertible Preferred Stock Authorized Shares	——	$40M0.0%	——	$40M—	——
Convertible Preferred Stock Issued Shares	——	$0—	——	$0—	——
Convertible Preferred Stock Outstanding Shares	——	0—	——	0—	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$5K—	$5K+25.0%	——	$4K—	——
Preferred Stock Par Value Per Share	——	$0.000.0%	——	$0.00—	——
Share-Based Payment - Nonvested Awards (Number)	——	$4.19M+56.7%	——	$2.67M+179%	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	$7.6M—	——	——	——
Accrued Research And Development Expenses	——	——	——	$86K—	——
Cash and cash equivalents, end of period	308,000,000%-108,200,000%	514,300,000%+52,200,000%	416,200,000%—	462,100,000%+461,900,000%	——
Common stock, par value (in dollars per share)	$0.00—	$0.000.0%	——	$0.00—	——
Common stock, shares authorized (in shares)	$560M—	$560M0.0%	——	$560M—	——
Common stock, shares issued (in shares)	$47.34M—	$47.34M+15.0%	——	$41.15M—	——
Common Stock, Shares, Outstanding	47.3M—	47.3M+15.0%	——	41.2M—	——
Deferred Tax Assets, Gross	——	$6.64M+24.6%	——	$5.33M—	——
Deferred Tax Assets, Net of Valuation Allowance	——	$250K-46.5%	——	$467K—	——
Deferred Tax Assets, Operating Loss Carryforwards	——	$4.74M+15.8%	——	$4.1M—	——
Deferred Tax Assets Patent License	——	$852K—	——	——	——
Deferred Tax Assets, Valuation Allowance	——	$6.39M+31.4%	——	$4.87M—	——
Deferred Tax Liabilities, Net	——	$250K-46.5%	——	$467K—	——
Deferred Tax Liabilities, Other	——	$250K-46.5%	——	$467K—	——
Cost not yet recognized	$7.6M—	$7.6M—	——	——	——
Operating Loss Carryforwards	——	$18.7M+19.1%	——	$15.7M—	——
Operating Loss Carryforwards Valuation Allowance	——	$1.5M—	——	——	——
Other accrued liabilities	——	$21K-75.9%	——	$87K—	——
Preferred Stock, Par or Stated Value Per Share	$0.00—	$0.000.0%	——	$0.00—	——
Preferred Stock, Shares Authorized	$40M—	$40M0.0%	——	$40M—	——
Preferred Stock, Shares Issued	$0—	$0—	——	$0—	——
Preferred Stock, Shares Outstanding	0—	0—	——	0—	——
Prepaid expenses	$389K—	——	——	$380K—	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number	$4.19M—	$4.19M+56.7%	——	$2.67M+179%	——
Shares Issued Price Per Share	——	——	$1.17—	——	——
Working Capital	$2.5M—	$4.6M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Polaryx Therapeutics, Inc. 's total assets?: Polaryx Therapeutics, Inc. (PLYX) holds $3.5M in total assets.
How much cash does Polaryx Therapeutics, Inc. have?: Polaryx Therapeutics, Inc. holds $3.1M in cash and equivalents.
Can Polaryx Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 3.45 — current assets exceed current liabilities.
Where does Polaryx Therapeutics, Inc. 's balance sheet data come from?: Every line is extracted from Polaryx Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.